



NAME: _____

UGA ID#: _____

Date of Birth: _____

Part I: Tuberculosis (TB) Screening Questionnaire

(To be completed by incoming students - 30 days prior to registering for class)

Please answer the following questions:

1. Have you ever had close contact with persons known or suspected to have active TB disease? Yes No
2. Were you born in one of the countries listed below that have a high incidence of active TB disease? Yes No

(If YES, please CIRCLE the country, below)

Afghanistan	Côte d'Ivoire	Kenya	Nicaragua	South Africa
Algeria	Democratic People's Republic of	Kiribati	Niger	South Sudan
Angola	Korea	Kuwait	Nigeria	Sri Lanka
Argentina	Democratic Republic of the	Kyrgyzstan	Niue	Sudan
Armenia	Congo	Lao People's Democratic	Pakistan	Suriname
Azerbaijan	Djibouti	Republic	Palau	Swaziland
Bahrain	Dominican Republic	Latvia	Panama	Taiwan
Bangladesh	Ecuador	Lesotho	Papua New Guinea	Tajikistan
Belarus	El Salvador	Liberia	Paraguay	Thailand
Belize	Equatorial Guinea	Libya	Peru	Timor-Leste
Benin	Eritrea	Lithuania	Philippines	Togo
Bhutan	Estonia	Madagascar	Poland	Trinidad and Tobago
Bolivia (Plurinational State of)	Ethiopia	Malawi	Portugal	Tunisia
Bosnia and Herzegovina	Fiji	Malaysia	Qatar	Turkey
Botswana	Gabon	Maldives	Republic of Korea	Turkmenistan
Brazil	Gambia	Mali	Republic of Moldova	Tuvalu
Brunei Darussalam	Georgia	Marshall Islands	Romania	Uganda
Bulgaria	Ghana	Mauritania	Russian Federation	Ukraine
Burkina Faso	Guatemala	Mauritius	Rwanda	United Republic of
Burundi	Guinea	Mexico	Saint Vincent and the	Tanzania
Cabo Verde	Guinea-Bissau	Micronesia	Grenadines	Uruguay
Cambodia	Guyana	(Federated States of)	Sao Tome and Principe	Uzbekistan
Cameroon	Haiti	Mongolia	Senegal	Vanuatu
Central African Republic	Honduras	Morocco	Serbia	Venezuela (Bolivarian
Chad	India	Mozambique	Seychelles	Republic of)
China	Indonesia	Myanmar	Sierra Leone	Viet Nam
Colombia	Iran (Islamic Republic of)	Namibia	Singapore	Yemen
Comoros	Iraq	Nauru	Solomon Islands	Zambia
Congo	Kazakhstan	Nepal	Somalia	Zimbabwe

Source: World Health Organization Global Health Observatory, Tuberculosis Incidence 2012. Countries with incidence rates of ≥ 20 cases per 100,000 population. For future updates, refer to <http://apps.who.int/ghodata>.

3. Have you had frequent or prolonged visits to one or more of the countries listed above with a high prevalence of TB disease? (If yes, CHECK the countries, above) Yes No
4. Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)? Yes No
5. Have you been a volunteer or health-care worker who served clients who are at increased risk for active TB disease? Yes No
6. Have you ever been a member of any of the following groups that may have an increased incidence of latent *M. tuberculosis* infection or active TB disease – medically underserved, low-income, or abusing drugs or alcohol? Yes No

If the answer is YES to any of the above questions, University Health Center requires that you receive TB testing.

If the answer to all of the above questions is NO, no further testing or further action is required.

Signature of Student _____

Date: _____

(Or Signature of Parent if student is < 18 yrs. old)



PART II. CLINICAL ASSESSMENT BY HEALTHCARE PROVIDER

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

History of a positive TB skin test or IGRA blood test? (If yes, document below) Yes No

History of BCG vaccination? (If yes, consider IGRA if possible.) Yes No

1. TB Symptom Check¹

Does the student have signs or symptoms of active pulmonary tuberculosis disease? Yes No

*If NO, proceed to 2 and 3. If YES, check below:

- Cough (especially if lasting for 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- Chest pain
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Fever

Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)

(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration as well as risk factors.)*

Date Given: / /
 M D Y

Date Read: / /
 M D Y

Result: _____mm of induration

**Interpretation: positive____negative____

Date Given: / /
 M D Y

Date Read: / /
 M D Y

Result: _____mm of induration

**Interpretation: positive____negative____

****Interpretation guidelines**

≥5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

≥10 mm is positive:

- Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

≥15 mm is positive:

- Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.



University Health Center

Student Affairs

UNIVERSITY OF GEORGIA

UNIVERSITY HEALTH CENTER

University of Georgia

Athens, GA 30602-1755

Phone: 706-542-1162

Fax Nr: 706-542-4959

or 706-583-0777

NAME: _____

UGA ID#: _____

Date of Birth: _____

3. Interferon Gamma Release Assay (IGRA)

Date Obtained: ___/___/___ (specify method) QFT-GIT T-Spot other____
M D Y

Result: negative___ positive___ indeterminate___ borderline__(T-Spot only)

Date Obtained: ___/___/___ (specify method) QFT-GIT T-Spot other____
M D Y

Result: negative___ positive___ indeterminate___ borderline__(T-Spot only)

4. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: ___/___/___ Result: normal___ abnormal____
M D Y

PART III: MANAGEMENT OF POSITIVE TST OR IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with *M. tuberculosis* (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunioileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

••Populations defined locally as having an increased incidence of disease due to *M. tuberculosis*, including medically underserved, low-income populations

____ Student agrees to receive treatment

____ Student declines treatment at this time

Required Signature of Healthcare Provider:

Name: _____

Phone: _____

Address: _____

City, State, Zip Code: _____

Signature: _____

Date: _____